ADVERUM BIOTECHNOLOGIES INC (ADVM) Stock Price, Quote, News and Overview
NASDAQ:ADVM - Nasdaq - US00773U2078 - Common Stock - Currency: USD
ADVM Quote, Performance and Key Statistics
3.59
+0.1 (+2.87%)
The current stock price of ADVM is 3.59 USD. In the past month the price decreased by -6.99%. In the past year, price decreased by -61.4%.
ADVM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.09 | 346.84B | ||
| AMGN | AMGEN INC | 13.49 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 128.59B | ||
| GILD | GILEAD SCIENCES INC | 13.28 | 128.00B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.62 | 65.17B | ||
| ARGX | ARGENX SE - ADR | 345.61 | 40.09B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.58B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.40B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.30B | ||
| NTRA | NATERA INC | N/A | 21.40B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.81B | ||
| BIIB | BIOGEN INC | 7.7 | 17.85B |
Related stock screener links
About ADVM
Company Profile
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company is headquartered in Redwood City, California and currently employs 155 full-time employees. The company went IPO on 2014-07-31. The firm discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. The company also developing an early-stage pipeline of gene therapy programs.
Company Info
ADVERUM BIOTECHNOLOGIES INC
100 Cardinal Way
Redwood City CALIFORNIA 94063 US
CEO: Laurent Fischer
Employees: 155
Phone: 16506491004
ADVERUM BIOTECHNOLOGIES INC / ADVM FAQ
What is the stock price of ADVERUM BIOTECHNOLOGIES INC today?
The current stock price of ADVM is 3.59 USD. The price increased by 2.87% in the last trading session.
What is the ticker symbol for ADVERUM BIOTECHNOLOGIES INC stock?
The exchange symbol of ADVERUM BIOTECHNOLOGIES INC is ADVM and it is listed on the Nasdaq exchange.
On which exchange is ADVM stock listed?
ADVM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ADVERUM BIOTECHNOLOGIES INC stock?
14 analysts have analysed ADVM and the average price target is 23.66 USD. This implies a price increase of 559.16% is expected in the next year compared to the current price of 3.59. Check the ADVERUM BIOTECHNOLOGIES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ADVERUM BIOTECHNOLOGIES INC worth?
ADVERUM BIOTECHNOLOGIES INC (ADVM) has a market capitalization of 75.00M USD. This makes ADVM a Micro Cap stock.
How many employees does ADVERUM BIOTECHNOLOGIES INC have?
ADVERUM BIOTECHNOLOGIES INC (ADVM) currently has 155 employees.
What are the support and resistance levels for ADVERUM BIOTECHNOLOGIES INC (ADVM) stock?
ADVERUM BIOTECHNOLOGIES INC (ADVM) has a resistance level at 4.02. Check the full technical report for a detailed analysis of ADVM support and resistance levels.
Is ADVERUM BIOTECHNOLOGIES INC (ADVM) expected to grow?
The Revenue of ADVERUM BIOTECHNOLOGIES INC (ADVM) is expected to decline by -84.17% in the next year. Check the estimates tab for more information on the ADVM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ADVERUM BIOTECHNOLOGIES INC (ADVM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ADVM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ADVM, evaluating the profitability, health, valuation and growth aspects
- ADVERUM BIOTECHNOLOGIES INC (ADVM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ADVERUM BIOTECHNOLOGIES INC (ADVM) Sales and EPS estimates to see what analysts future expectations are.
- ADVERUM BIOTECHNOLOGIES INC (ADVM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ADVERUM BIOTECHNOLOGIES INC (ADVM) Insider and Institutional Ownership to learn about the owners and their transactions.
- ADVERUM BIOTECHNOLOGIES INC (ADVM) Stock Chart to make your own analysis
- ADVERUM BIOTECHNOLOGIES INC (ADVM) Latest news and press-releases to stay up to date.
Does ADVERUM BIOTECHNOLOGIES INC (ADVM) stock pay dividends?
ADVM does not pay a dividend.
When does ADVERUM BIOTECHNOLOGIES INC (ADVM) report earnings?
ADVERUM BIOTECHNOLOGIES INC (ADVM) will report earnings on 2025-05-08, after the market close.
What is the Price/Earnings (PE) ratio of ADVERUM BIOTECHNOLOGIES INC (ADVM)?
ADVERUM BIOTECHNOLOGIES INC (ADVM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.65).
What is the Short Interest ratio of ADVERUM BIOTECHNOLOGIES INC (ADVM) stock?
The outstanding short interest for ADVERUM BIOTECHNOLOGIES INC (ADVM) is 8.48% of its float. Check the ownership tab for more information on the ADVM short interest.
ADVM Technical Analysis
ADVM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ADVM. While ADVM seems to be doing ok healthwise, there are quite some concerns on its profitability.
ADVM Financial Highlights
Over the last trailing twelve months ADVM reported a non-GAAP Earnings per Share(EPS) of -5.65. The EPS increased by 51.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -64.8% | ||
| ROE | -164.81% | ||
| Debt/Equity | 0 |
ADVM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ADVM. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 10.69% and a revenue growth -84.17% for ADVM